Key Documents

View All Documentation

SML1668

Tipifarnib

Name: Tipifarnib
Brand: SIGMA

≥98% (HPLC), FTase inhibitor, powder

Synonym(s):

(R)-(+)-R 115777, 6-[(R)-Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, R115777

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₇H₂₂Cl₂N₄O

CAS Number:

192185-72-1

Molecular Weight:

489.40

UNSPSC Code:

12352200

PubChem Substance ID:

329826003

NACRES:

NA.77

MDL number:

MFCD07772347

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

Tipifarnib, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D 17 to 24°, c = 1 in methanol

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

−20°C

SMILES string

CN(C1=CC=C([C@](C2=CN=CN2C)(N)C3=CC=C(Cl)C=C3)C=C1C(C4=CC=CC(Cl)=C4)=C5)C5=O

InChI

1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1

InChI key

PLHJCIYEEKOWNM-HHHXNRCGSA-N

Related Categories

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

General description

Pre-clinical studies show that tipifarnib has antiproliferative effects on pancreatic cancer cell lines at clinically relevant concentrations (concentration that inhibits 50% growth [IC50] from 9.5 to 500 nmol/L). It also exhibits marked growth retardation and antiangiogenic effects in a pancreatic cancer xenograft model.

Biochem/physiol Actions

Orally active and potent farnesyltransferase (FTase) inhibitor

Tipifarnib (R115777) is an orally active and potent farnesyltransferase (FTase) inhibitor that exhibits potent anti-tumorigenic effects. Tipifarnib mechanism of action is not fully understand.

pictograms

GHS07

signalword

Warning

hcodes

H315,H319,H335

pcodes

P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000378801

0000154221

0000091574

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

Van E C, et al.

Journal of Clinical Oncology, 22(8), 1430-1438 (2004)

Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis.

Madeleine Dorsch et al.

Cell reports, 37(8), 110056-110056 (2021-11-25)

Statins are among the most commonly prescribed drugs, and around every fourth person above the age of 40 is on statin medication. Therefore, it is of utmost clinical importance to understand the effect of statins on cancer cell plasticity and

Global Trade Item Number

SKU	GTIN
SML1668-25MG	04061832983738
SML1668-5MG	04061832983745

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service